



ABN 53 075 582 740

## ASX ANNOUNCEMENT

3 July 2020

# APPOINTMENT OF NEW DIRECTOR – MR AARON WEAVER

Bionomics Limited (ASX: BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company announced today that Mr Aaron Weaver has been appointed as a Non-Executive Director to the Board of Bionomics Limited from 6 July 2020.

Mr Weaver is a Managing Director at Apeiron Investments focused on the life sciences sector. He also serves as Senior General Counsel and supports fundraising and investor relations activities at ATAI Life Sciences AG, a clinical stage biopharmaceutical company focused on the development of therapeutics for the treatment of mood disorders, addiction and anxiety. He is a Chartered Financial Analyst (CFA) and a registered solicitor in the United Kingdom. From 2013 – 2017, he was an investment banker at Credit Suisse in London within the Capital Markets Solutions team, advising on capital structuring and issuances for a full spectrum of corporate issuers from pre-revenue companies to public listed companies. He was a capital markets solicitor at Allen & Overy LLP, London from 2007 – 2013. He holds a Masters of Law from the Queensland University of Technology and a Bachelor of Business Administration from the University of Queensland.

Mr Weaver is the nominee of Apeiron Investment Group Ltd (“Apeiron”) under the Subscription Agreement dated 1 June 2020 between the Company and Apeiron. Under that Agreement, Apeiron will subscribe or procure the subscription of, approximately A\$20-A\$22 million in total funding to progress BNC210 development for the treatment of PTSD.

The Executive Chairman of Bionomic Limited, Dr Errol De Souza said “We welcome Aaron to the Board. His commercial experience in the life sciences sector makes him an excellent addition to the Board as we progress BNC210 development for the treatment of PTSD”

**AUTHORISED BY THE BOARD.**

## FOR FURTHER INFORMATION PLEASE CONTACT:

Mr Jack Moschakis  
Legal Counsel & Company Secretary  
+61 8 8354 6181  
[jmoschakis@bionomics.com.au](mailto:jmoschakis@bionomics.com.au)

## About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of agitation, is a novel, proprietary negative allosteric modulator of the alpha-7 ( $\alpha 7$ ) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

[www.bionomics.com.au](http://www.bionomics.com.au)